Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jun;34(6):1327-1339.
doi: 10.1007/s12325-017-0521-z. Epub 2017 Apr 10.

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Sandra Adsit  1 , Enrique Rivas Zaldivar  2 , Howard Sofen  3 , Ignacio Dei-Cas  4 , César Maldonado-García  5 , Elkin O Peñaranda  6 , Luís Puig  7 , Xiangyi Meng  8 , Todd Fox  9 , Adriana Guana  8
Affiliations
Clinical Trial

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Sandra Adsit et al. Adv Ther. 2017 Jun.

Erratum in

Abstract

Introduction: There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients.

Methods: Data were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe plaque psoriasis. Patients who self-identified as Hispanic were included in the Hispanic subgroup.

Results: Efficacy responses (Psoriasis Area and Severity Index [PASI] 75/90/100 and Investigator's Global Assessment 2011 modified version 0/1) for secukinumab 300 mg were greater than for etanercept at week 12 in the Hispanic and non-Hispanic patient subgroups. At week 12 with secukinumab 300 mg, PASI 90/100 responses were achieved by 70.6%/35.9% of Hispanic patients and 58.0%/28.1% of non-Hispanic patients. At week 12 with secukinumab 150 mg, PASI 90/100 responses were achieved by 59.5%/25.1% of Hispanic patients and 41.2%/13.4% of non-Hispanic patients. In both subgroups, peak efficacy responses with secukinumab were observed at week 16 and were maintained to week 52.

Conclusions: Secukinumab is highly effective for clearing psoriasis in both Hispanic and non-Hispanic patients.

Funding: Novartis Pharmaceutical Corporation.

Keywords: Biologic therapy; Dermatology Life Quality Index; Hispanic; IL-17; Moderate-to-severe psoriasis; Non-Hispanic; Pooled analysis; Psoriasis Area and Severity Index; Secukinumab; Subcutaneous injection.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Composition of pooled study population by phase 3 trial. Etn etanercept, Sec secukinumab
Fig. 2
Fig. 2
Efficacy over time for Hispanic and non-Hispanic patients. n represents the number of evaluable subjects. Missing values were handled by multiple imputation. PASI 90/100 Psoriasis Area and Severity Index 90%/100% improvement from baseline
Fig. 3
Fig. 3
Efficacy over time by baseline PASI score a <20 and b ≥20 for Hispanic and Non-Hispanic patients. n represents the number of evaluable subjects. Missing values were handled by multiple imputation. PASI 90/100 Psoriasis Area and Severity Index 90%/100% improvement from baseline
Fig. 4
Fig. 4
Speed of response in Hispanic and non-Hispanic Patients. A repeated-measures, mixed-effects model was used to analyze the mean percentage change from baseline in PASI score. The median time to a 50% reduction in mean PASI score was estimated from parametric bootstrap samples with the use of linear interpolation between time points. PASI Psoriasis Area and Severity Index
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141:133–142. doi: 10.1111/imm.12142. - DOI - PMC - PubMed
    1. Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE) Br J Dermatol. 2015;172:484–493. doi: 10.1111/bjd.13348. - DOI - PubMed
    1. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371:326–338. doi: 10.1056/NEJMoa1314258. - DOI - PubMed
    1. Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE) J Eur Acad Dermatol Venereol. 2015;29:1082–1090. doi: 10.1111/jdv.12751. - DOI - PubMed
    1. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329–1339. doi: 10.1056/NEJMoa1412679. - DOI - PubMed

Publication types